Products ready for market-specific evaluation
Building a competitive portfolio requires more than access to a broad product catalogue. It requires identifying the opportunities that offer the strongest combination of portfolio relevance, differentiated presentations and potential commercial value.
Commercially Available Focus Products
Building a competitive portfolio requires more than access to a broad product catalogue. It requires identifying the opportunities that offer the strongest combination of portfolio relevance, differentiated presentations and potential commercial value.
Our commercially available focus portfolio highlights selected products that Medis believes deserve particular customer attention. The selection spans multiple therapeutic areas and includes opportunities with broad strength ranges, differentiated dosage forms and the potential to complement or expand established portfolios.
By bringing these products into focus, we aim to help our partners move efficiently from portfolio exploration to a more targeted assessment of the opportunities most relevant to their business. A product or dossier described as available may not be suitable for every country, and market-specific regulatory, supply and commercial considerations may apply.
For more information and to explore the suitability and timing of a pipeline opportunity for your desired market, please contact your relevant Medis Business Development Manager.
Cardiovascular Health
Amlodipine / Indapamide / Perindopril Arginine
A three-component fixed-dose combination opportunity for partners seeking to expand their cardiovascular portfolio.
- Dosage form: Film-coated tablet
- Strengths: 5 mg/1.25 mg/5 mg, 5 mg/2.5 mg/10 mg, 10 mg/1.25 mg/5 mg and 10 mg/2.5 mg/10 mg
- Therapeutic area: Cardiovascular
- Key indication: Hypertension
- Dossier status: Available
- Stability coverage: Zone IVb
The availability of four strength combinations supports different fixed-dose requirements and provides a broad commercial presentation.
Immunology and Dermatology
Apremilast
An oral product opportunity associated with immune-mediated conditions, including plaque psoriasis and psoriatic arthritis.
- Dosage form: Film-coated tablet
- Strengths: 10 mg, 20 mg and 30 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indications: Plaque psoriasis and psoriatic arthritis
- Product class: Immunosuppressant
- Dossier status: Available
- Stability coverage: Zone IVb
The three-strength presentation may be relevant to partners operating across dermatology, rheumatology and immunology portfolios.
Hematology and Supportive Care
Eltrombopag
A focused oral hematology opportunity associated with the management of thrombocytopenia.
- Dosage form: Film-coated tablet
- Strengths: 25 mg, 50 mg and 75 mg
- Therapeutic area: Blood and blood-forming organs
- Key indication: Thrombocytopenia
- Product class: Antihemorrhagic
- Dossier status: Available
- Stability coverage: Zone IVb
The three-strength presentation may complement specialty-care and hospital-focused portfolios.
Ferric Carboxymaltose
An intravenous product opportunity for partners active in hospital care, hematology and iron-deficiency management.
- Dosage form: Solution for injection or infusion
- Strength: 50 mg/ml
- Therapeutic area: Blood and blood-forming organs
- Key indication: Iron-deficiency anaemia
- Product class: Antianaemic preparation
- Dossier status: Available
- Stability coverage: Zone II
The injectable presentation may offer a relevant addition to hospital and specialty-care portfolios.
Filgrastim
A pre-filled syringe opportunity associated with supportive care and the management of neutropenia.
- Dosage form: Solution for injection in a pre-filled syringe
- Strengths: 30 MIU/0.5 ml and 48 MIU/0.8 ml
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Neutropenia
- Product class: Immunostimulant
- Dossier status: Available
- Stability coverage: Zone IVb
The two pre-filled syringe presentations may be relevant to partners developing oncology, hematology and supportive-care portfolios.
Gastroenterology
Esomeprazole Tablets
An established gastroenterology opportunity available in two widely recognised strengths.
- Dosage form: Gastro-resistant tablet
- Strengths: 20 mg and 40 mg
- Therapeutic area: Alimentary tract and metabolism
- Key indications: Duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux disease and Zollinger-Ellison syndrome
- Product class: Peptic ulcer and gastro-oesophageal disease treatment
- Dossier status: Available
- Stability coverage: Zone II
This commercially available tablet presentation should be differentiated from the separate Esomeprazole capsule reformulation listed later on this page.
Respiratory and Consumer Health
Levodropropizine Tablets
An oral solid presentation associated with the symptomatic relief of dry cough.
- Dosage form: Tablet
- Strength: 60 mg
- Therapeutic area: Respiratory system
- Key indication: Symptomatic relief of dry cough
- Product class: Cough suppressant
- Dossier status: Available
- Stability coverage: Zone II
The tablet format may be relevant to respiratory and consumer-health portfolios, subject to local classification and regulatory requirements.
Levodropropizine Oral Liquid
A complementary liquid presentation associated with the symptomatic relief of dry cough.
- Dosage form: Oral liquid
- Strength: 6 mg/ml
- Therapeutic area: Respiratory system
- Key indication: Symptomatic relief of dry cough
- Product class: Cough suppressant
- Dossier status: Available
- Stability coverage: Zone II
Together, the tablet and oral liquid presentations allow partners to consider a broader Levodropropizine portfolio with two distinct dosage forms.
Central Nervous System
Lisdexamfetamine
A broad-strength capsule opportunity associated with attention deficit hyperactivity disorder.
- Dosage form: Hard capsule
- Strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg
- Therapeutic area: Nervous system
- Key indication: Attention deficit hyperactivity disorder
- Product class: Psychoanaleptic
- Dossier status: Available
- Stability coverage: Zone IVb
Six available strengths provide a broad product presentation for partners building or expanding a central nervous system portfolio.
Melatonin
A prolonged-release oral product associated with circadian-rhythm sleep disorders.
- Dosage form: Prolonged-release tablet
- Strength: 2 mg
- Therapeutic area: Nervous system
- Key indication: Circadian-rhythm sleep disorders
- Product class: Hypnotic and sedative agent
- Dossier status: Available
- Stability coverage: Zone IVb
The prolonged-release dosage form may provide a differentiated opportunity within sleep-health and selected consumer-health portfolios, depending on local classification.
Important Product Information
Medis partners with pharmaceutical companies and does not supply medicines directly to patients or healthcare professionals.
The information presented on this page is intended exclusively for business-to-business discussions. Product specifications, dosage forms, strengths, indications, dossier status, development timing, manufacturing arrangements, intellectual-property position, registration pathway, marketing-authorization availability, supply conditions and launch timing may vary by country and may change.
A dossier described as available may not necessarily be immediately suitable for submission or commercial launch in every territory. Additional development, documentation, regulatory activities or market-specific requirements may apply.
Indications shown are high-level portfolio descriptors and do not constitute prescribing information, medical advice or confirmation of an approved indication in a particular country.
For detailed product information and to assess the suitability of an opportunity for your desired market, please contact your relevant Medis Business Development Manager.